Literature DB >> 25777093

Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy?

Maxine S Jochelson1, Katharine Lampen-Sachar, Girard Gibbons, Chau Dang, Diana Lake, Elizabeth A Morris, Monica Morrow.   

Abstract

BACKGROUND: Neoadjuvant chemotherapy (NAC) may allow breast-conserving therapy (BCT) in patients who require mastectomy at presentation. Breast MRI is more accurate than mammography in assessing treatment response, but combined test reliability in identifying BCT candidates after NAC is not well described. We evaluated whether post-NAC breast MRI alone and with mammography accurately identifies BCT candidates.
METHODS: In this retrospective study of 111 consecutive breast cancer patients receiving NAC, all had pre- and postchemotherapy MRI, followed by surgery. Posttreatment MRI and mammography results were correlated with surgical outcomes and pathologic response.
RESULTS: Fifty-one of 111 (46 %) patients presented with multicentric or inflammatory breast cancer and were not BCT candidates. The remaining 60 (54 %) were considered BCT candidates after downstaging (mean age: 47 years). All 60 had at least a partial response to NAC and were suitable for BCT on MRI after NAC. Forty-five of 60 (75 %) underwent lumpectomy; 15 of 60 (25 %) chose mastectomy. Forty-one of 45 (91 %) of lumpectomies were successful; 4 of 45 (9 %) required mastectomy. Twelve of 15 (80 %) patients choosing mastectomy could have undergone BCT based on pathology; 3 of 15 (20 %) did require mastectomy. Two of these three patients had extensive microcalcifications on mammogram, indicating the need for mastectomy despite MRI suitability for BCS. MRI alone correctly predicted BCS in 53 of 60 (88 %) patients. MRI plus mammography was correct in 55 of 60 (92 %), although only 9 of 45 (20 %) BCT patients and 4 of 15 (27 %) potentially conservable mastectomy patients had complete pathologic responses.
CONCLUSIONS: Posttreatment MRI plus mammography is an accurate method to determine whether BCT is possible after NAC is given to downstage disease.

Entities:  

Mesh:

Year:  2015        PMID: 25777093      PMCID: PMC4511096          DOI: 10.1245/s10434-015-4502-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  17 in total

1.  Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: a meta-analysis.

Authors:  Ying Yuan; Xiao-Song Chen; Shi-Yuan Liu; Kun-Wei Shen
Journal:  AJR Am J Roentgenol       Date:  2010-07       Impact factor: 3.959

2.  Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.

Authors:  A Charehbili; M N Wasser; V T H B M Smit; H Putter; A E van Leeuwen-Stok; W M Meershoek-Klein Kranenbarg; G J Liefers; C J H van de Velde; J W R Nortier; J R Kroep
Journal:  Eur J Surg Oncol       Date:  2014-08-08       Impact factor: 4.424

3.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.

Authors:  Davide Mauri; Nicholas Pavlidis; John P A Ioannidis
Journal:  J Natl Cancer Inst       Date:  2005-02-02       Impact factor: 13.506

4.  Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer.

Authors:  Eren Yeh; Priscilla Slanetz; Daniel B Kopans; Elizabeth Rafferty; Dianne Georgian-Smith; Linda Moy; Elkan Halpern; Richard Moore; Irene Kuter; Alphonse Taghian
Journal:  AJR Am J Roentgenol       Date:  2005-03       Impact factor: 3.959

5.  MRI and conservative treatment of locally advanced breast cancer.

Authors:  T Julius; S E G Kemp; P J Kneeshaw; A Chaturvedi; P J Drew; L W Turnbull
Journal:  Eur J Surg Oncol       Date:  2005-12       Impact factor: 4.424

6.  MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy.

Authors:  Marieke E Straver; Claudette E Loo; Emiel J T Rutgers; Hester S A Oldenburg; Jelle Wesseling; Marie-Jeanne T F D Vrancken Peeters; Kenneth G A Gilhuijs
Journal:  Ann Surg       Date:  2010-04       Impact factor: 12.969

7.  Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.

Authors:  Jeon-Hor Chen; Shadfar Bahri; Rita S Mehta; Aida Kuzucan; Hon J Yu; Philip M Carpenter; Stephen A Feig; Muqing Lin; David J B Hsiang; Karen T Lane; John A Butler; Orhan Nalcioglu; Min-Ying Su
Journal:  Radiology       Date:  2011-08-30       Impact factor: 11.105

8.  Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Authors:  José Baselga; Ian Bradbury; Holger Eidtmann; Serena Di Cosimo; Evandro de Azambuja; Claudia Aura; Henry Gómez; Phuong Dinh; Karine Fauria; Veerle Van Dooren; Gursel Aktan; Aron Goldhirsch; Tsai-Wang Chang; Zsolt Horváth; Maria Coccia-Portugal; Julien Domont; Ling-Min Tseng; Georg Kunz; Joo Hyuk Sohn; Vladimir Semiglazov; Guillermo Lerzo; Marketa Palacova; Volodymyr Probachai; Lajos Pusztai; Michael Untch; Richard D Gelber; Martine Piccart-Gebhart
Journal:  Lancet       Date:  2012-01-17       Impact factor: 79.321

9.  Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

Authors:  William M Sikov; Donald A Berry; Charles M Perou; Baljit Singh; Constance T Cirrincione; Sara M Tolaney; Charles S Kuzma; Timothy J Pluard; George Somlo; Elisa R Port; Mehra Golshan; Jennifer R Bellon; Deborah Collyar; Olwen M Hahn; Lisa A Carey; Clifford A Hudis; Eric P Winer
Journal:  J Clin Oncol       Date:  2014-08-04       Impact factor: 44.544

10.  Calcifications on mammogram do not correlate with tumor size after neoadjuvant chemotherapy.

Authors:  Anna Weiss; Katherine C Lee; Yajahira Romero; Erin Ward; Yeunjeong Kim; Haydee Ojeda-Fournier; John Einck; Sarah L Blair
Journal:  Ann Surg Oncol       Date:  2014-07-24       Impact factor: 5.344

View more
  6 in total

Review 1.  Surgical Management of Breast Cancer Treated with Neoadjuvant Therapy.

Authors:  Octavi Cordoba; Lourdes Carrillo-Guivernau; Carmen Reyero-Fernández
Journal:  Breast Care (Basel)       Date:  2018-07-25       Impact factor: 2.860

2.  Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial.

Authors:  Mehra Golshan; Sibylle Loibl; Stephanie M Wong; Jens Bodo Houber; Joyce O'Shaughnessy; Hope S Rugo; Norman Wolmark; Mark D McKee; David Maag; Danielle M Sullivan; Otto Metzger-Filho; Gunter Von Minckwitz; Charles E Geyer; William M Sikov; Michael Untch
Journal:  JAMA Surg       Date:  2020-03-18       Impact factor: 14.766

3.  Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised?

Authors:  Yara Feliciano; Anita Mamtani; Monica Morrow; Michelle M Stempel; Sujata Patil; Maxine S Jochelson
Journal:  Ann Surg Oncol       Date:  2017-01-05       Impact factor: 5.344

Review 4.  Overview of Breast Cancer Therapy.

Authors:  Tracy-Ann Moo; Rachel Sanford; Chau Dang; Monica Morrow
Journal:  PET Clin       Date:  2018-07

5.  Association of surgical margins with local recurrence in patients undergoing breast-conserving surgery after neoadjuvant chemotherapy.

Authors:  Joseph Lin; Kuo-Juei Lin; Yu-Fen Wang; Ling-Hui Huang; Sam Li-Sheng Chen; Dar-Ren Chen
Journal:  BMC Cancer       Date:  2020-05-20       Impact factor: 4.430

6.  Accuracy and Reproducibility of Contrast-Enhanced Mammography in the Assessment of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients with Calcifications in the Tumor Bed.

Authors:  Valentina Iotti; Moira Ragazzi; Giulia Besutti; Vanessa Marchesi; Sara Ravaioli; Giuseppe Falco; Saverio Coiro; Alessandra Bisagni; Elisa Gasparini; Paolo Giorgi Rossi; Rita Vacondio; Pierpaolo Pattacini
Journal:  Diagnostics (Basel)       Date:  2021-03-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.